Treatment with calcimimetics in kidney transplantation

Transplantation Reviews

Volumn 24, Issue 2, 2010, Pages 79-88

  Morales, Enrique ^a   Gutierrez, Eduardo ^a   Andres, Amado ^a  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; BISPHOSPHONIC ACID DERIVATIVE; CALCIMIMETIC AGENT; CALCINEURIN INHIBITOR; CALCIUM; CINACALCET; PARATHYROID HORMONE; RAPAMYCIN; STEROID; VITAMIN D;

BONE DISEASE; BONE MASS; BONE METABOLISM; BONE MINERAL; BONE NECROSIS; BONE PAIN; CALCIUM BLOOD LEVEL; CALCIUM METABOLISM; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG WITHDRAWAL; FRACTURE; GASTROINTESTINAL DISEASE; HUMAN; HYPERPARATHYROIDISM; HYPOPHOSPHATEMIA; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; METABOLIC DISORDER; MYALGIA; NUTRITIONAL INTOLERANCE; OSTEOLYSIS; OSTEOPOROSIS; PARATHYROID HORMONE BLOOD LEVEL; PARATHYROIDECTOMY; PHOSPHATE METABOLISM; PHOSPHATE URINE LEVEL; POSTOPERATIVE COMPLICATION; QUALITY OF LIFE; REVIEW; RISK FACTOR; SIDE EFFECT; URINARY EXCRETION; VITAMIN D DEFICIENCY;

EID: 77950851582     PISSN: 0955470X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trre.2010.01.001     Document Type: Review

References (89)

1. Brandenburg V.M., Westenfeld R., Ketteler M. The fate of bone after renal transplantation. J Nephrol 2004, 17:190-204.
2. Heaf J.G. Bone disease after renal transplantation. Transplantation 2003, 75:315-323.
3. Torres A., Lorenzo V., Salido E. Calcium metabolism and skeletal problems after transplantation. J Am Soc Nephrol 2002, 13:551-558.
4. Coco M., Glicklich D., Faugere M.C., et al. Prevention of bone loss in renal transplant recipients: a prospective, randomized trial of intravenous pamidronate. J Am Soc Nephrol 2003, 14:2669-2676.
5. Torres A., García S., Gómez A., et al. Treatment with intermittent calcitriol and calcium reduces bone loss after renal transplantation. Kidney Int 2004, 65:705-712.
6. Kruse A.E., Eisenberger U., Frey F.J., Mohaupt M. The calcimimetic cinacalcet normalizes serum calcium in renal transplant patients with persistent hyperparathyroidism. Nephrol Dial Transplant 2005, 20:1311-1314.
7. Srinivas T.R., Schold J.D., Womer K.L., et al. Improvement in hypercalcemia with cinacalcet after kidney transplantation. Clin J Am Soc Nephrol 2006, 1:323-326.
8. Bergua C., Torregrosa J.V., Fuster D., Gutierrez-Dalmau A., Oppenheimer F., Campistol J.M. Effect of cinacalcet on hypercalcemia and bone mineral density in renal transplanted patients with secondary hyperparathyroidism. Transplantation 2008, 86:413-417.
9. Kunzerdorf U., Krämer B.K., Arns W., et al. Bone disease after renal transplantation. Nephrol Dial Transplant 2008, 23:450-458.
10. Eknoyan G., Levin A., Levin N.W. K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease. Am J Kidney Dis 2003, 42:S1-S266.
11. Evenepoel P., Claes K., Kuypers D., Maes B., Bammens B., Vanrenterghem Y. Natural history of parathyroid function and calcium metabolism after kidney transplantation: a single-centre study. Nephrol Dial Transplant 2004, 19:1281-1287.
12. Dumoulin G., Hory B., Nguyen N.U., et al. No trend toward a spontaneous improvement of hyperparathyroidism and high bone turnover in normocalcemic long-term renal transplant recipients. Am J Kidney Dis 1997, 29:746-753.
13. Heaf J., Tvedegaard E., Kanstrup I.L., Fogh-Andersen N. Bone loss after renal transplantation: role of hyperparathyroidism, acidosis, cyclosporine and systemic disease. Clin Transplant 2000, 14:457-463.
14. Messa P., Sindici C., Cannella G., et al. Persistent secondary hyperparathyroidism after renal transplantation. Kidney Int 1998, 13:436-442.
15. Torregrosa J.V., Campistol J.M., Fenollosa B., Montesinos M., Romar A., Martinez de Osaba M.J. Role of secondary hyperparathyroidism in the development of post-transplant acute tubular necrosis. Nephron 1996, 73:67-72.
16. Rodríguez M., Felsenfeld A.J., Llach F. Calcemic response to parathyroid hormone in renal failure: role of phosphorus and its effect on calcitriol. Kidney Int 1991, 40:1055-1062.
17. Julian B.A., Quarles L.D., Niemann K.M. Musculoskeletal complications after renal transplantation: pathogenesis and treatment. Am J Kidney Dis 1992, 19:99-120.
18. Kurella M., Butterly D.W., Smith S.R. Post transplant erythrocytosis in hypercalcemic renal transplant recipients. Am J Transpl 2003, 3:873-877.
19. Campese V.M. Calcium, parathyroid hormone, and blood pressure. Am J Hypertens 1989, 2:34-44.
20. Leapman S.B., Vidne B.A., Butt K.M., Waterhouse K., Kountz S.L. Nephrolithiasis and nephrocalcinosis after renal transplantation: a case report an review of the literature. J Urol 1976, 115:129-132.
21. Gwinner W., Suppa S., Mengel M., et al. Early calcification of renal allografts detected by protocol biopsies: causes and clinical implications. Am J Transplant 2005, 5:1934-1941.
22. García-Cantón C., Palomar R., Moreno A., et al. Evolution of anemia of chronic renal failure after the treatment of hyperparathyroidism. Nephron 1996, 74:444-445.
23. Shutz-Swirski R., Shkolnik T., Shasha S.M. Parathyroid hormone and the cellular immune system. Nephron 1995, 70:21-24.
24. Ambuhl P.M., Meier D., Wolf B., Dydak U., Boesiger P., Binswanger U. Metabolic aspects of phosphate replacement therapy for hypophosphatemia after renal transplantation: impact on muscular phosphate content, mineral metabolism, and acid/base homeostasis. Am J Kidney Dis 1999, 34:875-883.
25. Green J., Debby H., Lederer E., Levi M., Zajicek H.K., Bick T. Evidence for a PTH-independent humoral mechanism in post-transplant hypophosphatemia and phosphaturia. Kidney Int 2001, 60:1182-1196.
26. Bhan I., Shah A., Holmes J., et al. Post-transplant hypophosphatemia: "tertiary hyper-phosphatoninism"?. Kidney Int 2006, 70:1486-1494.
27. 3 production. J Biol Chem 2003, 278:2206-2211.
28. Briner V.A., Thiel G., Monier-Faugere M.C., et al. Prevention of cancellous bone loss but persistence of renal bone disease despite normal 1,25 vitamin D levels two years after kidney transplantation. Transplantation 1995, 59:1393-1400.
29. Lim W.H., Coates P.S., Russ G.R., Coates P.T. Hyperparathyroidism and vitamin D deficiency predispose to bone loss in renal transplant recipients. Transplantation 2009, 88:678-683.
30. Epstein S. Post-transplantation bone disease: the role of immunosuppressive agents and the skeleton. J Bone Miner Res 1996, 11:1-7.
31. Massari P.U. Disorders of bone and mineral metabolism after renal transplantation. Kidney Int 1997, 52:1412-1421.
32. O'Shaughnessy E.A., Dahl D.C., Smith C.L., Kasiske B.L. Risk factors for fractures in kidney transplantation. Transplantation 2002, 74:362-366.
33. Tang G., Chan T.M., Lui S.L., Li F.K., Lo W.K., Lai K.N. Risk factors for avascular bone necrosis after renal transplantation. Transplant Proc 2000, 32:1783-1875.
34. Goffin E., Vandeberg B., Devogelaer J.P., et al. Post-renal transplant syndrome of transient lower limb joint pain: description under tacrolimus-based immunosuppression. Clin Nephrol 2003, 59:98-105.
35. Block G.A., Klassen P.S., Lazarus J.M., Ofsthun N., Lowrie E.G., Chertow G.M. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004, 15:2208-2218.
36. EBPG Expert Group on Renal Transplantation: European Best Practice Guidelines for renal transplantation. Section IV: Long term management of the transplant recipient. Nephrol Dial Transplant 2002, 17:S43-S48.
37. Rojas E., Carlini R.G., Clesca P., et al. The pathogenesis of osteodystrophy after renal transplantation as detected by early alterations in bone remodeling. Kidney Int 2003, 63:1915-1923.
38. Schmid T., Muller P., Spelsberg F. Parathyroidectomy after renal transplantation: a retrospective analysis of long-term outcome. Nephrol Dial Transplant 1997, 12:2393-2396.
39. Lewin E., Olgaard K. Parathyroidectomy vs calcimimetics for treatment of persistent hyperparathryroidism after kidney transplantation. Nephrol Dial Transplant 2006, 21:1766-1769.
40. Rostaing L., Moreau-Gaudry X., Baron E., Cisterne J.M., Monroziès-Bernadet P., Durand D. Changes in blood pressure and renal function following subtotal parathyroidectomy in renal transplant patients presenting with persistent hypercalcemic hyperparathyroidism. Clin Nephrol 1997, 47:248-255.
41. Garcia A., Mazuecos A., Garcia T., Gonzalez P., Ceballos M., Rivero M. Effect of parathyroidectomy on renal graft function. Transplant Proc 2005, 37:1459-1461.
42. Lee P.P., Schiffmann L., Offermann G., Beige J. Effects of parathyroidectomy on renal allograft survival. Kidney Blood Press Res 2004, 27:191-196.
43. Evenepoel P., Claes K., Kuypers D., Maes B., Vanrenterghem Y. Impact of parathyroidectomy on renal graft function, blood pressure and serum lipids in kidney transplant recipients: a single centre study. Nephrol Dial Transplant 2005, 20:1714-1720.
44. Block G.A., Martin K.J., de Francisco A.L., et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 2004, 350:1516-1525.
45. Cunningham J., Danese M., Olson K., Klassen P., Chertow G.M. Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int 2005, 68:1793-1800.
46. Rodríguez M., Nemeth E., Martín D. The calcium-sensing receptor: a key factor in the pathogenesis of secondary hyperparathyroidism. Am J Physiol Renal Physiol 2005, 288:F253-F264.
47. Lindberg J.S., Moe S.M., Goodman W.G., et al. The calcimimetic AMG 073 reduces parathyroid hormone and calcium × phosphorus in secondary hyperparathyroidism. Kidney Int 2003, 63:248-254.
48. Coburn J.W., Elangovan L., Goodman W.G., Frazao J.M. Calcium-sensing receptor and calcimimetic agents. Kidney Int 1999, 73:S52-S58.
49. Ishii H., Wada M., Furuya Y., Nagano N., Nemeth E.F., Fox J. Daily intermittent decreases in serum levels of parathyroid hormone have an anabolic-like action on the bones of uremic rats with low-turnover bone and osteomalacia. Bone 2000, 26:175-182.
50. Colloton M., Shatzen E., Miller G., et al. Cinacalcet HCl attenuates parathyroid hyperplasia in a rat model of secondary hyperparathyroidism. Kidney Int 2005, 67:467-476.
51. Ogata H., Ritz E., Odoni G., Amann K., Orth S.R. Beneficial effects of calcimimetics on progression of renal failure and cardiovascular risk factors. J Am Soc Nephrol 2003, 14:959-967.
52. Ureña P., Frazão J. Calcimimetic agents: Review and perspectives. Kidney Int 2003, 63:91-96.
53. David D.S., Sakai S., Brennan B.L., et al. Hypercalcemia after renal transplantation. Long-term follow-up data. N Engl J Med 1973, 289:398-401.
54. Egbuna O.I., Taylor J.G., Bushinsky D.A., Zand M.S. Elevated calcium phsophate product after renal transplantation is a risk factor for graft failure. Clin Transplant 2007, 21:558-566.
55. Serra L.A., Schwarz A.A., Wick F.H., Marti H.P., Wüthrich R.P. Successful treatment of hypercalcemia with cinacalcet in renal transplant recipients with persistent hyperparathyroidism. Nephrol Dial Transplant 2005, 20:1315-1319.
56. Szwarc I., Argilés A., Garrigue V., Delmas S., Chong G., Deleuze S., Mourad G. Cinacalcet chloride is efficient and safe in renal transplant recipients with posttransplant hyperparathyroidism. Transplantation 2006, 82:675-680.
57. Apostolou T., Kollia K., Damianou L., et al. Hypercalcemia due to resistant hyperparathyroidism in renal transplant patients treated with calcimmetic agent cinacalcet. Transplant Proc 2006, 38:3514-3516.
58. Leca N., Laftavi M., Gundroo A., et al. Early and severe hyperparathyroidism associated with hypercalcemia after renal transplant treated with cinacalcet. Am J Transplant 2006, 6:2391-2395.
59. Serra A., Savoca R., Huber A.R., et al. Effective control of persistent hyperparathyroidism with cinacalcet in renal allograft recipients. Nephrol Dial Transplant 2007, 22:577-583.
60. Bergua C., Torregrosa J.V., Cofán F., Oppenheimer F. Cinacalcet for the treatment of hypercalcemia in renal transplanted patients with secondary hyperparathyroidism. Transplant Proc 2007, 29:2254-2255.
61. El-Amm J.M., Doshi M.D., Singh A., et al. Preliminary experience with cinacalcet use in persistent secondary hyperparathyroidism after kidney transplant. Transplantation 2007, 28:546-549.
62. Borchhardt K.A., Heinzl H., Mayerwöger E., Hörl W.H., Hass M., Sunder-Plassmann G. Cinacalcet increases calcium excretion in hyepercalcemic hyperparathyroidism after kidney transplantation. Transplantation 2008, 86:919-924.
63. Gómez G., Obrador A., Vilar A., et al. Treatment with cinacalcet of secondary hyperparathyroidism after renal transplantation. Transplant Proc 2009, 41:2139-2143.
64. Toro F.J., Bernal G., Navarro M., et al. Calcimimetics and bone mineral density in renal transplant patients with persistent secondary hyperparathyroidism. Transplant Proc 2009, 41:2144-2147.
65. López V., Toledo R., Sola E., et al. Treatment with cinacalcet in 29 kidney transplant patients with persistent hyperparathyroidism. Transplant Proc 2009, 41:2394-2395.
66. Morales E., Gutierrez E., Bengoa I., et al. Effectiveness of cinacalcet in the treatment of hypercalcemia after renal transplantation. J Am Soc Nephrol 2009, 20:883A. (PUB253).
67. Murer H., Hernando N., Forster L., Biber J. Molecular mechanisms in proximal tubular and small intestinal phosphate reabsortion. Mol Membr Biol 2001, 18:3-11.
68. Peacok M., Bilezikian J.P., Klassen P.S., Guo M.D., Turner S.A., Shoback D. Cinacalcet hydrochloride maintains long normocalcemia in patients with primary hyperparathyroidism. J Clin Endocrinol Metab 2005, 90:135-141.
69. Withold W., Friedrich W., Degenhardt S. Serum bone alkaline phosphatase is superior to plasma levels of bone matrix proteins for assessment of bone metabolism in patients receiving renal transplants. Clin Chim Acta 1997, 261:105-115.
70. 2+ transport proteins by parathyroid hormone. Kidney Int 2005, 68:1708-1721.
71. Esposito L., Rostaing L., Gennero I., Mehrenberger M., Durand D., Kamar N. Hypercalciuria induced by high dose of cinacalcet in a renal-transplant recipient. Clin Nephrol 2007, 68:245-248.
72. Misael da Silva A.M., dos Reis L.M., Pereira R.C., et al. Bone involvement in idiopathic hypercalciuria. Clin Nephrol 2002, 57:183-191.
73. Ohkido I., Segawa H., Yanagida R., Nakamura M., Miyamoto K. Cloning, gene structure and dietary regulation of the type-IIc Na/pi cotransporter in the mouse kidney. Pflugers Arch 2003, 446:106-115.
74. Shimada T., Yamazaki Y., Muto T., et al. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci U S A 2001, 98:6500-6505.
75. Serra A.L., Wuhrmann C., Wüthrich R.P. Phosphatemic effect of cinacalcet in kidney transplant recipients with persistent hyperparathyroidism. Am J Kidney Dis 2008, 52:1151-1157.
76. Wada N., Nagano N., Furuya Y., Chin J., Nemeth E.F., Fox J. Calcimimetic NPS R-568 prevents parathyroid hyperplasia in rats with severe secondary hyperparathyroidism. Kidney Int 2000, 57:50-58.
77. Lien Y.H., Silva A.L., Whittman D. Effects of cinacalcet on bone mineral density in patients with secondary hyperparathyroidism. Nephrol Dial Transplant 2005, 20:1232-1237.
78. Cunningham J., Danese M., Olson K., Klassen P., Chertow G.M. Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health related quality of life in secondary hyperparathyroidism. Kidney Int 2005, 68:1793-1800.
79. Decleire P.Y., Devogelaer J.P., Goffin E. Cinacalcet improves bone mineral density in a renal transplant recipient with persistent hyperparathyroidism. Clin Nephrol 2008, 69:231-232.
80. Sprague S.M., Josephson M.A. Bone disease after kidney transplantation. Semin Nephrol 2004, 24:82-90.
81. Peng L.W., Logan J.L., James S.H., Scout K.M., Lien Y.H.H. Cinacalcet associated graft dysfunction and nephrocalcinosis in a kidney transplant recipient. Am J Med 2007, 120:e7-e9.
82. Lee C.T., Huynh V.M., Lai L.W., lien Y.H. Cyclosporine A induced hypercalciuria in calbidin-D28K knockout and wild type-mice. Kidney Int 2002, 62:2055-2061.
83. Kruse A.E., Eisenberger U., Frey F.J., Mohaupt M.G. Effect of cinacalcet cessation in renal transplant recipients with persistent hyperparathyroidism. Nephrol Dial Transplant 2007, 22:2362-2365.
84. Wada M., Ishii H., Furuya Y., Fox J., Nemeth E.F., Nagano N. NPS R-568 halts or reverses osteitis fibrosa in uremia rats. Kidney Int 1998, 53:448-453.
85. Levi R., Ben-Dov I.Z., Lavi-Moshayoff V., et al. Increased parathyroid hormone gene expression in secondary hyperparathyroidism of experimental uremia is reserved by calcimimetics: correlation with post-translational modification of the transacting factor AUF1. J Am Soc Nephrol 2006, 17:107-112.
86. Rodriguez M.E., Almaden Y., Canadillas S., et al. The calcimimetics R 568 increases vitamin D receptor expresión in rat parathyroid glands. Am J Physiol Renal 2007, 292:390-395.
87. Torregrosa J.V., Bergua C., Martínez de Osaba M.J., Oppenheimer F., Campistol J.M. Evolution of secondary hyperparathyroidism after kidney transplantation in patients receiving cinacalcet on diálisis. Transplant Proc 2009, 41:2396-2398.
88. Leonard N., Brown J.H. Persistent and symptomatic post-transplant hyperparathyroidism: a dramatic response to cinacalcet. Nephrol Dial Transplant 2006, 21:1736.
89. White R.E., Pickering A., Spathis G.S. Mood disorder and chronic hypercalcemia. J Psychosom Res 1996, 41:343-347.